- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab, Placebo
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Laguna Niguel, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Cincinnati, Ohio
- Conditions
- Mild to Moderate Alzheimer's Disease
- Interventions
- GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg
- Drug
- Lead sponsor
- GemVax & Kael
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 12
- States / cities
- Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more
- Conditions
- Hepatitis C
- Interventions
- Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin, Placebo
- Biological · Drug · Other
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,095 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more
- Conditions
- Allergic Rhinitis Due to Cat Allergy
- Interventions
- REGN1908-1909, Matching Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 42
- States / cities
- Mission Viejo, California • Riverside, California • Rolling Hills Estates, California + 39 more
- Conditions
- Crohn's Disease
- Interventions
- Double-blind (DB) adalimumab placebo, DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg
- Biological
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 43
- States / cities
- Berkeley, California • Long Beach, California • San Diego, California + 36 more
- Conditions
- Healthy
- Interventions
- PF-06823859, Placebo injection SC/IV
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Placebo (for alirocumab), Atorvastatin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 38
- States / cities
- Tempe, Arizona • Los Angeles, California • Mission Viejo, California + 33 more
- Conditions
- Chronic Pain, Back Pain Lower Back Chronic, Back Pain, Low
- Interventions
- Open-Label Placebo Treatment for Chronic Back Pain, Psychotherapy Treatment for Chronic Back Pain
- Other · Behavioral
- Lead sponsor
- University of Colorado, Boulder
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boulder, Colorado
- Conditions
- Healthy, Dermatitis, Atopic
- Interventions
- LY3844583, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Atopic Dermatitis
- Interventions
- Rocatinlimab, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 726 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 69
- States / cities
- Litchfield Park, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 58 more
- Conditions
- Colitis Ulcerative
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 27
- States / cities
- Apple Valley, California • Beverly Hills, California • Oxnard, California + 24 more
- Conditions
- Graft vs. Host Disease
- Interventions
- Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Healthy Participants
- Interventions
- Lu AG22515, Placebo, Immune System Activator
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 19 Years to 60 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Long Beach, California • Secaucus, New Jersey
- Conditions
- Primary Sclerosing Cholangitis (PSC)
- Interventions
- Simtuzumab, Placebo
- Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 34 more
- Conditions
- Compensated Cirrhosis, Nonalcoholic Steatohepatitis
- Interventions
- aldafermin, Placebo
- Biological · Other
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 31
- States / cities
- Glendale, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 22 more
- Conditions
- Uveitis
- Interventions
- Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab
- Drug
- Lead sponsor
- XOMA (US) LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 52
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 49 more
- Conditions
- Anemia in Chronic Kidney Disease Patients Not on Dialysis
- Interventions
- Darbepoetin alfa, Placebo
- Biological · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 756 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 243
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 198 more
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder
- Interventions
- Dupilumab SAR231893, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Roseville, California • Stockton, California • Denver, Colorado + 7 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- ISIS 104838
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Los Angeles, California + 23 more
- Conditions
- Familial Hypercholesterolemia - Homozygous
- Interventions
- Inclisiran, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more
- Conditions
- Asthma
- Interventions
- Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
- Conditions
- Subcutaneous Abdominal Adiposity
- Interventions
- LIPO-102, Placebo
- Drug
- Lead sponsor
- Neothetics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Anaheim, California • San Diego, California
- Conditions
- ALS (Amyotrophic Lateral Sclerosis)
- Interventions
- Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Monthly placebo infusions + 3 times per week placebo injections
- Biological · Other
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas